Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?
Gastric cancer remains a major health issue and a leading cause of death worldwide. While the incidence is decreasing in western countries, there has been a shift to more proximal cancers of the diffuse type, which are usually more aggressive and associated with a worse prognosis. Radical surgery still offers the only chance of long term survival, but surgery has reached a plateau of effectiveness and more aggressive approaches like "ultraradical" lymphadenectomy have not improved prognosis. There are three options to improve the situation: Earlier detection, neoadjuvant chemotherapy and adjuvant therapy. Whilst systematic gastroscopic screening makes sense in countries with a high incidence of gastric cancer, in other regions targeted investigation of risk groups including first-degree relatives of cancer patients, patients with a chronic corpus-dominant gastritis or with defined genetic abnormalities may help to detect cancer at an earlier stage. Neoadjuvant chemotherapy has meanwhile proved to significantly improve the prognosis not only in patients with a locally advanced cancer who cannot be resected for cure but but also in those who are potentially amenable to curative resection. In the largest randomised study so far reported, perioperative chemotherapy raised overall survival after 5 years from 23% to 36%. The role of adjuvant chemotherapy has been discussed for over 30 years. Meta-analyses demonstrate a small but significant effect which, however, seems to be restricted to Asian patients. In a large US-study, adjuvant radiochemotherapy appeared to significantly improve outcomes. However, less than 50% of the study patients underwent a systematic lymphadenectomy and so the results of the therapy group were not better to those of "only resected" patients in two large European studies. Thus, the indication of adjuvant (radio-)chemotherapy in gastric cancer currently remains uncertain. Endoscopists have found a therapeutic role through endoscopic resection of early cancers, introduced mainly by Japanese authors. With the development of high resolution endoscopy, endosonography and adequate equipment, the endoscopic curative resection of T1a-tumors (restricted to the mucosal layer) has been established.
Markus Menges, Department of Internal Medicine, Division of Gastroenterology, Diakonie-Hospital, 74523 Schwaebisch Hall, Germany.
Markus
M
Menges
J Natl Cancer Inst. 2007 Apr 18;99(8):601-7
17440161
Ann Oncol. 2000 Jul;11(7):837-43
10997811
Eur J Cancer. 1999 Jul;35(7):1059-64
10533448
Ann Oncol. 2005 Sep;16(9):1488-97
15939717
Hepatogastroenterology. 2008 May-Jun;55(84):1131-5
18705345
Cancer. 1993 Oct 1;72(7):2089-97
8374867
J Clin Oncol. 1993 Aug;11(8):1441-7
8336183
N Engl J Med. 2001 Sep 6;345(10):725-30
11547741
Hum Pathol. 1986 May;17(5):482-7
3699811
N Engl J Med. 2006 Jul 6;355(1):11-20
16822992
Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001964
15495024
World J Gastroenterol. 2006 Jan 21;12(3):354-62
16489633
Recent Results Cancer Res. 2000;155:1-14
10693234
Br J Surg. 2005 Jan;92(1):5-13
15635680
J Am Coll Surg. 1998 Oct;187(4):352-7
9783780
J Gastrointest Surg. 2000 Sep-Oct;4(5):520-5
11077328
Langenbecks Arch Surg. 2007 Mar;392(2):131-4
17089174
Lancet. 1995 Mar 25;345(8952):745-8
7891484
Eur J Surg. 2002;168(11):597-608
12699095
Tumori. 2002 Jan-Feb;88(1):21-7
12004845
Hum Mol Genet. 1999 Apr;8(4):607-10
10072428
World J Gastroenterol. 2006 Aug 14;12(30):4873-4
16937471
Ann Oncol. 2006 Feb;17(2):262-9
16293676
Br J Cancer. 1999 Mar;79(9-10):1522-30
10188901
Langenbecks Arch Surg. 2009 Jan;394(1):105-13
18626657
Gastric Cancer. 1998 Dec;1(1):64-70
11957045
J Cancer Res Clin Oncol. 2009 Jan;135(1):29-38
18523800